PubMed Health⌕ Search

Biomedical subjects

M T Liu

Publications and source records attributed to M T Liu.

63 records · Page 4Linked to original sources
PubMed1990

[Blood group hemagglutinins in hens' eggs. 2. Comparison of immunohematological properties of serum and egg yolk hemagglutinins of hens immunized with OSe saliva].

Hens were immunized intraperitoneally with OSe saliva mixed with Freund's complete adjuvant, and the properties of hemagglutinins in sera and egg yolk were compared. Both serum and egg yolk hemagglutinins agglutinated O, A1, B and A1B erythrocytes to a similar degree, and both showed somewhat stronger agglutinating potencies at 5 degrees C than at 25 degrees C or 37 degrees C. The degrees of agglutination were little improved by the addition of 20% BSA or PVP medium solution for potentiating incomplete agglutinin. The antiglobulin-augmentation reaction with specific anti-chicken-Igs revealed that the principal immunoglobulins of the serum hemagglutinins produced during the early and hyperimmune phases of immune response were IgM and IgG, respectively; whereas the presence in egg yolk of both IgM and IgG hemagglutinins was demonstrated throughout the antibody producing periods. The yolk probably contained IgM incomplete hemagglutinins, because addition of an antiserum to chicken-IgM strongly enhanced the yolk hemagglutinin. The secretor status of six saliva specimens, OSe, Ose, ASe, Ase, BSe and Bse, was tested by the agglutinin-inhibition reaction using one of the following reagents: Ulex lectin, chicken antiserum, and egg yolk hemagglutinin. High inhibition titers of OSe saliva were obtained with the serum hemagglutinin (of the early and hyperimmune phases) and the yolk hemagglutinin of the eggs laid in the hyperimmune phase. The test with Ulex lectin showed a moderate grade of inhibition, and the use of yolk hemagglutinin produced in the early stage of immune response resulted in very low inhibition titers. Yolk hemagglutinins produced in the early and hyperimmune stages were more strongly inhibited by ASe and BSe salivas than by other hemagglutinin reagents. These results indicate the availability of blood group agglutinins in the yolks of eggs laid during the hyperimmune stage.

ABO Blood-Group System↗
PubMed1988

Biphasic pulp blood-flow response to substance P in the dog as measured with a radiolabelled, microsphere injection method.

A dose of the vasoactive substance P (SP), affecting local circulation only (0.0001-0.001 micrograms/kg body weight) when given by a close injection into the maxillary artery, caused a biphasic flow response in pulpal blood flow (PBF), as measured by a radioisotope-labelled 15 micron microsphere injection technique. Immediately after the SP injection, PBF increased some 66 per cent (p less than 0.02) and vascular hindrance (Z) decreased to 40 per cent against control values (p less than 0.02), indicating vasodilation. Thirty seconds after the SP injection, PBF decreased by 53 per cent (p less than 0.05), and pulpal Z increased 139 per cent against control values (p less than 0.02), indicating decreased blood flow. This biphasic flow response may be due to the active vasodilation of arterioles by SP, which causes a compression of venules and hence a reduction of PBF in what is a low-compliance system.

Animals↗
PubMed1985

Indirect enzyme-linked immunosorbent assay for the mycotoxin zearalenone.

A competitive indirect enzyme-linked immunosorbent assay (ELISA) was developed for the detection of zearalenone, an estrogenic mycotoxin. Zearalenone was converted to zearalenone-6'-carboxymethyloxime and conjugated to bovine serum albumin and poly-L-lysine for use as immunogen and solid-phase marker, respectively. Immunization of rabbits with the bovine serum albumin conjugate resulted in zearalenone antibody titers of 20,480 in 11 weeks. A competitive indirect ELISA was conducted by simultaneously incubating zearalenone with zearalenone antiserum over zearalenone-6'-carboxymethyloxime poly-L-lysine solid phase and then determining the bound rabbit immunoglobulin with goat anti-rabbit peroxidase conjugate. Response range for zearalenone in the resulting competition curve was between 1 and 50 ng/ml. Reactivities of this antiserum for alpha-zearalenol, beta-zearalenol, alpha-zearalanol, and beta-zearalanol were, respectively, 50, 12, 6, and 3% of that found for zearalenone. By using the competitive indirect ELISA, zearalenone was detectable in methanol-water extracts of corn, wheat, and pig feed samples.

Animal Feed↗
PubMedDate not supplied

Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).

INTRODUCTION: Epstein-Barr virus (EBV) is a ubiquitous human herpes virus with worldwide infection. It is associated with Burkitt's lymphoma in Africa and nasopharyngeal cancer (NPC) in Asian countries. EBV-coded DNA was found to be present in epithelial elements of NPC, and is usually associated with non-keratinizing (WHO type II) or undifferentiated carcinoma (WHO type III). Transcriptional analyses of EBV genome expression in NPC demonstrate an activated viral state in some of these tumors, leading to elevated levels of serum anti-viral capsid antigen (VCA) antibody in NPC patients. METHODS: Eighty patients with histological diagnoses of NPC according to the 1978 WHO classification were referred to the Department of Radiation Oncology at Chang-Hua Christian Hospital for curative radiotherapy from 1985 to 1995. The patients were staged according to the AJCC staging system. A mean dose of 7,020 cGy in 39 fractions was delivered to the primary tumor using a telecobalt-60 unit or 6-10 MV X-ray linear accelerator. Pre- and postradiotherapy serum levels of anti-EBV/VCA IgG and IgA were determined for all patients using the indirect immunoperoxidase assay (IPA). Multivariate analysis was done to determine which factors affected the patients' treatment outcome and survival. RESULTS: Five patients were excluded from this study due to incomplete radiotherapy, leaving 75 patients eligible for analysis. Overall local control was 77.3%, with a mean disease-free interval of 19.7 months. Factors affecting local control included radiation dose and pretreatment anti-EBV/VCA IgG titer. The overall 5-year actuarial survival for the 75 patients was 75%, with a median survival of 129.5 months. The 5-year actuarial survival rates for stage I + II, III, and IV patients were 90%, 40%, and 45%, respectively. Prognostic factors for survival included tumor histological type and pretreatment anti-EBV/VCA IgA titer, while prognostic factors for local control included total radiation dose received and pretreatment anti-EBV/VCA IgG titer. CONCLUSION: We found that there was a significant difference in the geometric mean titer of anti-EBV/VCA IgA antibodies before and after radiotherapy. Prognostic factors affecting NPC patients' actuarial survival included tumor histology and pretreatment IgA titer, while prognostic factors for local control of NPC included total radiation dose received and pretreatment IgG titer.

Adult↗